Subtype
Superficial Basal Cell Carcinoma
CI-CAN-00006851Explore in graph →
5 active trials1 approved drugs
- NCIt
- C62284
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006851Explore in graph →
Clinical trials
18 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04552990 | Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma | completed | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05381597 | 5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer | recruiting | Phase 2 / Phase 3 | 200 | Boston UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma |
| completed |
| Phase 1 / Phase 2 |
| 186 |
| BPGbioINDUSTRY |
| 1 |
| Feb 28, 2025 |
| clinicaltrials |
| NCT04470726 | Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype(NMSC) | completed | Phase 1 / Phase 2 | 26 | AiViva BioPharma, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05713760 | Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults | completed | Phase 2 | 5 | Austin Institute for Clinical ResearchNETWORK | 1 | Jul 19, 2024 | clinicaltrials |
| NCT05157763 | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 32 | MediWound LtdINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT01325688 | PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities | completed | Phase 2 | 75 | PeplinINDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00432185 | To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC | completed | Phase 2 | 117 | PeplinINDUSTRY | 1 | Feb 15, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jun 18, 2026source: clinicaltrials